Atorvastatin for Patients with Chronic Myeloproliferative Neoplasms

We are studying whether atorvastatin can improve health markers in patients with specific blood disorders. This trial looks at its effects alongside standard treatments to see how it may help manage symptoms and disease progression.

3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOralHematologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Atorvastatin
Atorvastatin is a substance that lowers bad cholesterol to help reduce the risk of heart attacks and strokes.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Atorvastatin

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Region Sjaelland
Hæmatologisk afdeling
Roskilde, Denmark
Sponsor: Region Sjaelland
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.